ATX
3 706
0,8%
DAX
20 451
0,9%
Dow
42 518
0,5%
EStoxx50
5 012
0,6%
Nasdaq
20 757
-0,1%
Öl
80,2
-0,2%
Euro
1,0299
-0,1%
CHF
0,9396
-0,1%
Gold
2 683
0,2%
ATX
3 706
0,9%
DAX
20 453
0,9%
Dow
42 518
0,5%
EStoxx50
5 014
0,7%
Nasdaq
20 757
-0,1%
Öl
80,1
-0,3%
Euro
1,0299
-0,1%
CHF
0,9396
-0,1%
Gold
2 684
0,3%
Depot
Menu
+ Börse
Aktien
Aktienkurse
Aktien-Suche
Realtimekurse
ATX-Liste
ATX Prime-Liste
EuroStoxx-Liste
DAX-Liste
Dow Jones-Liste
Nikkei225-Liste
S&P500-Liste
Rohstoffe
Devisen
Listen
TopFlop
Indizes
Branchen
Termine
Hauptversammlung
Quartalszahlen
Wirtschaftsdaten
Dividendenausschüt.
Dividenden
Börse-Social
Female Finance
Indizes
Listen
TopFlop
Indizes
Realtimekurse
Indizes
Listen
Emerging Markets
Zertifikate
Suche
Basiswerte
Indizes
Aktien
Baskets
Währungen
Rohstoffe
Zinsen / Anleihen
Sonstige
Produkttypen
Airbag
Aktienanleihen
Alpha
Basket
Bonus
Discount
Exotische OS
Express
Faktor Tracker
Index/Tracker
Inline-OS
Garantie
Knock-Out
Optionsscheine
Outperformance
sonst. Zertifikate
Sprint
Tools
Zertifikate-Matrix
Emittenten-Matrix
Knock-Out Map
News
Neuemissionen
Hebelprodukte
OS-Suche
KO-Suche
Basiswerte
Indizes
Aktien
Baskets
Währungen
Rohstoffe
Zinsen / Anleihen
Sonstige
Produkttypen
Airbag
Aktienanleihen
Alpha
Basket
Bonus
Discount
Exotische OS
Express
Faktor Tracker
Index/Tracker
Inline-OS
Garantie
Knock-Out
Optionsscheine
Outperformance
sonst. Zertifikate
Sprint
Tools
Zertifikate-Matrix
Emittenten-Matrix
Knock-Out Map
News
Neuemissionen
Fonds
Suche
News
KVGs
ETF
Suche
News
KVGs
Anleihen
Suche
News
Rohstoffe
News
Realtimekurse
Goldmünzen
Devisen
News
Währungsrechner
Realtimekurse
Kryptowährungen
Krypto-Broker Vergleich
Zinsen
News
Libor
Euribor
Leitzins
CFDs
News
Trading
Hebelprodukte
Optionsscheine
Realtimekurse
ATX-Liste
ATX Prime-Liste
EuroStoxx-Liste
DAX-Liste
Rohstoffe
Devisen
Bitcoin kaufen
Kryptos
Broker-Vergleiche
Broker-Vergleich
Krypto-Broker-Vergleich
CFD-Broker-Vergleich
Forum
+ News & Analysen
News
Ressorts
Aktien
Anleihen
CFDs
Devisen
ETF
Fonds
Rohstoffe
Zertifikate
Private Finanzen
Zinsen
Rubriken
Chartanalysen
Emittentennews
Fondsgesellschaft News
Heute im Fokus
Interviews
Konjunktur
Zinsen
Quellen
APA
Aktiencheck
Businesswire
Dow Jones Newswires
dpa-AFX
Heute im Fokus
Nachrichtenarchiv
Analysen
Experten Kolumnen
ATX News
+ myfinanzen
Anmelden
Registrieren
Passwort vergessen
Mein Profil
Portfolio
Watchlist
ZERO Depot
ETF-Sparplan
Krypto kaufen
Ratgeber
Suchen
Anmelden
Registrieren?
Fan werden
Börse
News & Analysen
myfinanzen
ZERO Depot
ETF-Sparplan
Krypto kaufen
Ratgeber
News
Analysen
Experten Kolumnen
ATX News
Ressorts
Aktien
Anleihen
CFDs
Devisen
ETF
Fonds
Rohstoffe
Zertifikate
Private Finanzen
Zinsen
Rubriken
Chartanalysen
Emittentennews
Fondsgesellschaft News
Heute im Fokus
Interviews
Konjunktur
Zinsen
Quellen
APA
Aktiencheck
Businesswire
Dow Jones Newswires
dpa-AFX
Heute im Fokus
Nachrichtenarchiv
Home
»
Aktien
»
ONCODESIGN-Aktie
»
Nachrichten zu ONCODESIGN
ONCODESIGN Aktie [WKN DE: A1107T / ISIN: FR0011766229]
Kurse + Charts + Realtime
News + Analysen
Fundamental
Unternehmen
zugeh. Wertpapiere
Aktion
Kurs + Chart
Chart (groß)
News + Adhoc
Bilanz/GuV
Termine
Zertifikate
Portfolio
Times + Sales
Chartvergleich
Analysen
Schätzungen
Profil
Optionsscheine
Watchlist
Börsenplätze
Realtime Push
Kursziele
Dividende/GV
Knock-Outs
Analysen
<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
Nachrichten zu ONCODESIGN SA
Relevant
Alle
vom Unternehmen
07.11.18
Service Partnership Agreement between Oncodesign and Galderma
(Businesswire)
18.05.18
Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago
(Businesswire)
30.01.18
Oncodesign: Strong Growth in Operating Revenue in 2017
(Businesswire)
18.12.17
Oncodesign: Promising clinical Results for Innovative Mutated anti-EGFR Radiotracer in Patients with Non-Small Cell Lung Cancer
(Businesswire)
18.12.17
Oncodesign: Promising Clinical Results for Innovative Mutated Anti-EGFR Radiotracer in Patients with Non-Small Cell Lung Cancer
(Businesswire)
05.12.17
Oncodesign Reports Positive Results for Its MNK1/2 Program
(Businesswire)
15.11.17
Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase
(Businesswire)
15.11.17
Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase
(Businesswire)
18.10.17
ONCODESIGN: OncoSNIPE® Artificial Intelligence Project Officially Launched
(Businesswire)
18.10.17
OncoSNIPE® Artificial Intelligence Project Officially Launched
(Businesswire)
05.10.17
Oncodesign Launches Its New Website
(Businesswire)
19.09.17
Oncodesign: First-Half 2017 Results
(Businesswire)
31.08.17
Oncodesign Announces the Acquisition of Bertin Pharma’s Pharmaceutical and Biotech Services Businesses
(Businesswire)
20.07.17
Oncodesign: Stable Revenue in the First Half of 2017
(Businesswire)
21.11.16
ONCODESIGN Wins the 4th European Small and Mid-Cap Awards in the "Rising Star” Category
(Businesswire)
17.11.16
Oncodesign: 2017-2020 strategic plan
(Businesswire)
28.09.16
GSK and Oncodesign Announce Agreement for Oncodesign’s Acquisition of GSK’s Research Centre in France
(Businesswire)
19.09.16
Oncodesign: First-Half 2016 Results
(Businesswire)
18.07.16
Oncodesign: Revenue for the First Half of 2016: €5.7 Million
(Businesswire)
12.07.16
Oncodesign Announces the Launch of Its First Clinical Study on a Radiotracer in Patients with Non-Small Cell Lung Cancer
(Businesswire)
12.07.16
Oncodesign announces the launch of its first clinical study on a radiotracer in patients with non-small cell lung cancer
(Businesswire)
30.05.16
Oncodesign is Granted New Patent Protecting Key Molecules Generated from Its Nanocyclix Technology Platform for Next Generation Kinase Inhibitors
(Businesswire)
03.05.16
Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen’s Paris-Saclay Campus
(Businesswire)
29.03.16
Oncodesign: Full-year 2015 Results: Major Improvement
(Businesswire)
20.01.16
Oncodesign Doubles Its Revenue in 2015
(Businesswire)
11.01.16
Oncodesign Announces Its Financial Calendar for 2016
(Businesswire)
05.01.16
Oncodesign Biotechnology and Bristol-Myers Squibb Enter into Strategic Drug Discovery Collaboration
(Businesswire)
05.01.16
Oncodesign Biotechnology and Bristol-Myers Squibb Enter into Strategic Drug Discovery Collaboration
(Businesswire)
17.12.15
Preclinical Validation of Oncodesign’s First Radiotracer Prior to Human Application
(Businesswire)
17.12.15
Preclinical Validation of Oncodesign’s First Radiotracer Prior to Human Application
(Businesswire)
21.10.15
Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago
(Businesswire)
16.10.15
Oncodesign Pursues Its Strategy of Expansion in North America
(Businesswire)
15.09.15
Oncodesign: First Half 2015 Results: Significant Improvement Alongside R&D Intensification
(Businesswire)
21.07.15
Oncodesign: 1st half of 2015 total revenue increases 93%
(Businesswire)
16.07.15
ONCODESIGN Announces the Creation of Its Scientific Advisory Board
(Businesswire)
05.06.15
UCB Exercises Its Option to License a Program from Oncodesign Targeting Neurological Diseases
(Businesswire)
02.06.15
UCB exercises its option to license a program from Oncodesign targeting neurological diseases
(Businesswire)
28.04.15
ONCODESIGN Presents New Supportive Data for Its Nanocyclix Based RIPK2 Program for Auto-Immune Disease at the 10th Drug Discovery Chemistry Conference in San Diego, CA
(Businesswire)
31.03.15
ONCODESIGN: Solid Operating Performance in 2014
(Businesswire)
26.03.15
Oncodesign Signs Additional 2-Year Preclinical Research Contract to Evaluate Antibody-Drug Conjugates
(Businesswire)
20.01.15
ONCODESIGN: 2014 Annual Revenue
(Businesswire)
15.01.15
Oncodesign Announces Its Financial Calendar for 2015
(Businesswire)
17.12.14
Oncodesign Has Entered into a Services Agreement with Eisai to Develop a New Personalized Medicine Program in Earlier Line Metastatic Breast Cancer Treatment
(Businesswire)
17.12.14
Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment
(Businesswire)
04.11.14
Oncodesign Announces the Third Extension of a Research Contract with Isarna Therapeutics
(Businesswire)
13.10.14
Oncodesign Seals a Major Research Agreement with Cellectis
(Businesswire)
29.09.14
Oncodesign Announces the Discovery of New Molecule Inhibitors of Inflammatory Disease and the Publication of 3 New Patent Applications
(Businesswire)
22.07.14
ONCODESIGN: 1st Half of 2014
(Businesswire)
22.07.14
ONCODESIGN: 1st Half of 2014
(Businesswire)
Eintrag hinzufügen
Eintrag bearbeiten
Hinweis:
Sie möchten dieses Wertpapier günstig handeln?
Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision
*
pro Trade?
Hier informieren!
Erfolgreich hinzugefügt!
Zu Portfolio/Watchlist wechseln
.
Es ist ein Fehler aufgetreten!
Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben.
Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.
Portfolioname:
Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:
15.01.2025 14:10
Kaufwert:
EUR
Hinzufügen
Speichern
Newssuche
GO
Meistgelesene Nachrichten
Diese AI-Aktie ist Cathie Woods neuer Favorit
JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy
NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab
ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren
Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an
D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter